Jci_page_head_homepage_01 Jci_page_head_homepage_02
Mingquan Zheng, Alistair J. Ramsay, Myles B. Robichaux, Karen A. Norris, Corrine Kliment, Christopher Crowe, Rekha R. Rapaka, Chad Steele, Florencia McAllister, Judd E. Shellito, Luis Marrero, Paul Schwarzenberger, Qiu Zhong, Jay K. Kolls
Published in Volume 115, Issue 12
J Clin Invest. 2005; 115(12):3536–3544 doi:10.1172/JCI26306
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7

Functionality and antigen specificity of serum after pKexin/CD40L vaccination in mice. (A) Opsonic activity of serum after DNA immunization with control, pKexin, or pKexin/CD40L vectors. (B) Passive transfer of serum or CD19+ splenocytes confers protection against a PC challenge in SCID mice. n = 4–6. All data are mean values ± SEM. *P < 0.05, **P < 0.01 compared with control. (C) Representative Western blot analysis of serum after Kexin vaccination against sonicated PC antigen. Neither naive serum nor serum from CD4-depleted mice with active PC infection gave any activity on Western blotting. Serum from mice undergoing 3 rounds of pKexin/CD40L vaccination (far right 2 lanes) reacted with a 105- and 55-kDa protein. (D) Representative immunofluorescent staining of mouse and monkey PC with anti-Kexin serum.